Antiarrhythmic Prophylaxis During VT Storm Ablation
Ventricular tachycardia storm is a medical emergency in which sustained ventricular tachycardia or ventricular fibrillation recurs rapidly. It commonly means three or more episodes in 24 hours, or sustained ventricular tachycardia requiring intervention; recurrent ventricular tachycardia is often defined as three or more episodes over six months. Repeated episodes can cause haemodynamic instability, syncope, acute heart failure, cardiac arrest and implantable cardioverter-defibrillator shocks. The shocks may provoke further arrhythmia through sympathetic activation and shortened refractoriness, creating a self-reinforcing electrical storm.
The central issue is not simply choosing a drug; it is deciding when therapy should bridge to definitive electrophysiological treatment. The focused question is the prophylactic use of antiarrhythmic drugs during radiofrequency catheter ablation for ventricular tachycardia storm. Prophylaxis may mean treatment started before the procedure, a temporary procedural adjunct, or maintenance therapy after ablation. These uses have different evidence and risks, yet are often grouped together. An agent that suppresses ventricular tachycardia during preparation may also obscure the arrhythmia needed for mapping.
Most storms occur with structural heart disease, including prior myocardial infarction and cardiomyopathy, although myocarditis, hypertrophic cardiomyopathy and idiopathic ventricular fibrillation can also be involved. Substrate, ventricular rate, blood pressure, ventricular function and reversible precipitants shape management. True prophylaxis has weaker evidence than acute treatment. The aim is not to suppress every premature ventricular contraction; it is to prevent sustained, shock-producing or haemodynamically consequential recurrence while arranging a durable electrophysiological solution.
Immediate Management and the Role of Ablation
Immediate care follows resuscitation principles: establish monitoring and intravenous access, correct important potassium or magnesium abnormalities, and use synchronised cardioversion for unstable sustained ventricular tachycardia. Defibrillation is indicated for ventricular fibrillation or pulseless rhythms. On Australian wards and in emergency departments, “defib” and “electrical storm” are familiar shorthand, but terminology should not delay treatment. An antiarrhythmic infusion may be needed while ablation is arranged, particularly for recurrent or poorly tolerated episodes.
Before ablation, look for reversible precipitants: acute ischaemia, hypoxia, electrolyte disturbance, infection, endocrine abnormalities and proarrhythmic medicines. Correcting these can reduce recurrence. Scar-related re-entry after myocardial infarction, cardiomyopathy or myocarditis may persist despite correction. In such patients, repeated shocks and haemodynamic collapse support urgent ventricular tachycardia ablation rather than indefinite drug treatment.
Drugs buy time. They may control episodes during transfer, permit cardioversion, or reduce shocks before electrophysiology. That benefit must be balanced against the possibility that a stable, suppressed rhythm is masking a circuit that will return as the drug concentration falls. The operative plan should include haemodynamic support and a strategy for remapping if arrhythmia becomes non-inducible under antiarrhythmic cover.
What the Evidence Supports
Evidence for antiarrhythmic prophylaxis around ventricular tachycardia ablation is largely observational. No adequately powered randomised trial has established that starting amiodarone or sotalol before radiofrequency ablation prevents ventricular tachycardia storm afterward. Registries have linked treatment with lower in-hospital recurrence, but patients given these drugs often have more severe disease. Confounding by indication makes it difficult to separate drug effect from underlying risk.
During ablation, antiarrhythmic drugs can suppress clinical and inducible ventricular tachycardia. This may help maintain blood pressure, yet it can also make target circuits harder to identify and reduce apparent procedural success. Non-inducibility while medicated is therefore a less dependable endpoint than freedom from clinically relevant tachycardia off treatment. Some centres accept this trade-off in unstable patients; others remap after drug clearance or change strategy when the rhythm cannot be induced.
A useful framework separates treatment before admission or transfer, temporary cover during the procedure, and maintenance suppression after ablation. For each, the team should define the target arrhythmia, agent, route, contraindications, monitoring, duration and review date. Prophylaxis is most defensible when recurrence risk is high, toxicity is manageable, and ablation is unlikely to be completed promptly. A drug given “just in case” without a documented purpose and stopping plan is difficult to audit and may complicate subsequent care.
Selecting the Antiarrhythmic Drug
Intravenous amiodarone is commonly used for sustained ventricular tachycardia and is often selected when storm is recurrent or haemodynamic compromise is present. Its broad ventricular coverage is useful, but infusion can worsen hypotension or bradycardia. Oral loading before elective ablation has little evidence for routine prophylaxis, and amiodarone’s long half-life makes any pre-procedure withdrawal deliberate, because recurrence during that interval can be dangerous.
Procainamide is an alternative intravenous option when appropriate, especially if amiodarone is ineffective or contraindicated. It requires close blood-pressure and electrocardiographic monitoring because it can cause hypotension and QRS prolongation; active metabolites may accumulate in renal impairment. Lidocaine may be an adjunct in pulseless ventricular tachycardia or ventricular fibrillation, but it is not interchangeable with a comprehensive strategy for recurrent sustained ventricular tachycardia. Use should follow local resuscitation and electrophysiology protocols.
For longer-term suppression, a beta-blocker is foundational when tolerated, particularly with heart failure or prior myocardial infarction. Sotalol can be useful in selected stable patients, but renal function, QT interval, bradycardia and drug interactions determine safety. Flecainide and propafenone are inappropriate for most scar-mediated ventricular tachycardia in structural heart disease. Amiodarone remains valuable when alternatives fail or recurrence is severe, provided pulmonary, thyroid, hepatic, ocular and interaction risks are managed. Monitoring and deprescribing should be planned from the outset.
Radiofrequency Ablation and Device Management
Radiofrequency catheter ablation is a substrate-based treatment that interrupts re-entry circuits responsible for scar-related ventricular tachycardia. Electrophysiologists use pacing manoeuvres, electroanatomical mapping and ablation of late potentials or abnormal electrograms to define and eliminate relevant circuits. Prophylactic antiarrhythmic cover can suppress inducibility or change morphology. In difficult cases, a short-acting agent may stabilise the patient, followed by remapping after clearance when feasible.
The procedural target extends beyond the tachycardia occurring that day. Clinicians seek electrocardiographic correlation, test for other inducible circuits, and eliminate clinically relevant substrate while avoiding unnecessary myocardial injury. Haemodynamic support, from vasopressors to extracorporeal support in selected refractory cases, may be required. Medication cannot replace complete lesion delivery or a reliable strategy for recurrent storm.
Device interrogation belongs within the same plan. Rapid ventricular tachycardia can trigger inappropriate implantable cardioverter-defibrillator shocks, while atrial fibrillation, lead noise or programming errors can act as triggers. Detection zones, antitachycardia pacing and shock therapy should be reviewed. When ventricular pacing is also required, His-bundle pacing may offer better synchrony than routine right ventricular pacing. A useful comparative resource is the journal’s bundle pacing review for evaluating those trade-offs.
Australian Practice and Long-Term Care
Australian geography makes timing part of the clinical decision. Patients in regional New South Wales, northern Queensland or Western Australia may need transfer from a regional hospital to a metropolitan electrophysiology centre, and ventricular tachycardia can recur during that interval. Units in Melbourne, Sydney, Brisbane, Perth and Adelaide differ in access to advanced ablation and mechanical circulatory support. Aeromedical retrieval and, in eligible remote settings, the Royal Flying Doctor Service influence both pre-procedure drug cover and how long it can safely continue.
Access and reimbursement operate through a mixed public and private system. Public patients generally receive specialist care through Medicare-reimbursed public hospitals, while private health insurance supports many elective procedures. The Therapeutic Goods Administration regulates medicines and implantable devices, and the Pharmaceutical Benefits Scheme subsidises eligible outpatient prescriptions; it does not ordinarily fund inpatient ablation drugs. These distinctions matter when prolonged amiodarone or sotalol is used while awaiting a procedure or transfer.
Patients with hypertrophic cardiomyopathy require careful device selection. A subcutaneous implantable cardioverter-defibrillator avoids transvenous leads but does not provide pacing or antitachycardia pacing, so suitability depends on rhythm history and individual risk. The journal’s subcutaneous ICD selection review outlines important considerations. A transvenous or hybrid system may be more appropriate when bradycardia, pacing dependence, atrial fibrillation or another antitachycardia strategy is expected.
After ablation, care should extend beyond procedural freedom from ventricular tachycardia. Remote device monitoring, cardiology review, general-practice follow-up and early electrophysiology reassessment can identify recurrent shocks, toxicity or renewed heart failure. Guideline-directed heart-failure therapy, potassium and magnesium maintenance, sleep and psychosocial care, and advice about driving and exercise help prevent another storm. In remote Australian communities, shared local follow-up and written escalation instructions can reduce delays when symptoms recur.
The most defensible approach is selective, monitored antiarrhythmic use linked to a clear peri-procedural purpose. Drugs can stabilise recurrent ventricular tachycardia and reduce shocks, but they should not obscure the substrate, delay correction of reversible causes or substitute for complete radiofrequency ablation. Device programming, long-term heart-failure care and an explicit review or stopping plan are equally important to preventing another electrical storm.
Journal of Arrhythmia invites clinicians and researchers to contribute original studies, reviews, case series and practical protocols that advance electrophysiological care. Submissions, questions about the journal’s scope and proposals for themed collections can be directed through the contact the editorial team page.